CA
NZ
UK
AU
IND
US
Management said its Enterprise segment continues to see underlyingDemandfor Pro AV managed switches, but that revenue is constrained byManufacturingoutput at a contract manufacturer bringing a new factory online. It said the constraint would persist into the first quarter of 2027, that Enterprise revenue would …
IBTROZI is approved in the United States for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, and U.S. sales are the company's only source of product revenue. Net product revenue was USD 27.46 million for the quarter and USD 69.16 …
Sales of USD 691.5 million compare with USD 669.9 million in the third quarter of 2025, and the company stated sales growth of 3.2% and core sales growth of 2.7%.Gross Profitwas USD 400.6 million against USD 370.2 million. Cost of sales included the receipt …
Other, net was a gain of USD 38 million, against USD 4 million in the prior-year quarter, and the company said the REA India gain and higher Total Segment EBITDA were the main drivers of net income.Net Incomerose to USD 215 million from USD …
Total investment income was USD 392.1 million against USD 453.1 million. Interest income from investments was USD 287.2 million against USD 359.9 million, which the company attributed to a smaller portfolio after net repayments of approximately USD 1.88 billion and a weighted average portfolioYieldof …
The company runs two segments, Specialty Carbon Black and Rubber Carbon Black. Management described global tire industry conditions as mixed in the quarter. Passenger car original equipment demand remained soft in Europe and North America, while replacement demand was more resilient, particularly for truck …
The 2026 private placement raised aggregate gross proceeds of approximately USD 150.0 million. The company issued 26,713,638 shares of common stock and pre-funded warrants for 9,430,957 shares, and agreed to use the proceeds for research and development in its vascular anomalies and breast cancer …
Management described driving adoption of Tablo in the acute care setting as its primary focus to date. It is also working with skilled nursing facilities, long-term acute care hospitals and other post-acute providers, and it plans to use its existing commercial infrastructure to broaden …
Management named the largest component of the lower top line. A single large environmental event generated USD 45.4 million of revenue in the prior-year quarter, and nothing comparable appeared this year. Excluding that event, the company stated, consolidated revenue increased approximately 13.1%. Net Service …
Net revenue was USD 1,493.5 million, which the company stated was 4.1% above the prior year. Infusion services net revenue was USD 1,466.8 million, with other revenue of USD 26.8 million. Gross profit was USD 285.0 million against USD 272.9 million, and the gross …
Please wait processing your request...